Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure

Hepatology Research

Volumn 39, Issue 12, 2009, Pages 1198-1207

  Zou, Zhengsheng ^a   Xu, Dongping ^a   Li, Baosen ^a   Xin, Shaojie ^a   Zhang, Zheng ^a   Huang, Lei ^b   Fu, Junliang ^a   Yang, Yongping ^a   Jin, Lei ^a   Zhao, Jing Min ^a   Shi, Ming ^a   Zhou, Guangde ^a   Sun, Yanling ^b   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Acute on chronic liver failure; Hepatitis B virus; Immulogically competent cells; Immunohistochemistry; Liver infiltrating lymphocytes

Indexed keywords

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CIRRHOSIS; LIVER FAILURE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL;

EID: 73849149220     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00571.x     Document Type: Article

References (26)

1. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 (Suppl. 2): 5-13.
2. Xing T, Li L, Cao H et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2006; 147: 184-8.
3. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252-61.
4. Wasmuth HE, Kunz D, Yagmut E et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201.
5. Liu CL, Fan ST, Lo CM et al. Liver-donor liver transplatation for acute-on-chronic hepatitis B liver failure. Transplantation 2003; 76: 1174-9.
6. Anonymous. Management scheme of diagnositic and therapy criteria of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 324-9.
7. Ke WM, Ye YN, Huang S. Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B. J Gastroenterol 2003; 38: 861-4.
8. Zou Z, Chen J, Xin S et al. Features of chronic severe hepatitis in 520 cases with chronic severe hepatitis. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002; 16: 246-8.
9. Wang Y, Chen Y, Gu C, Jiang L, Xiang D. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 261-3.
10. Shimizu T, Tokushige K, Yamaaguchi N et al. Discrimination of two different clinical entities, acute-type and subacute-type, human fulminant hepatitis by peripheral blood lymphpcyte subsets. J Gastroenterol Hepatol 1999; 14: 274-80.
11. Zhang Z, Zou Z, Fu J et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 2008 2008; 49: 396-406.
12. Xu D, Fu J, Jin L et al. CD4+CD25+ regulatory T cells in circulation and liver actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.
13. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.
14. Duan XZ, Wang M, Li H, Zhuang H, Xu D, Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 2004; 24: 637-47.
15. Zhou GD, Zhao JM, Wang SS et al. Clinical and pathological analysis on characteristics of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 483-6.
16. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
17. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
18. Streetz K, Leifeld L, Grundmann D et al. Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000; 119: 446-60.
19. Gough DB, Fearon KC, Carter D.C. Metabolic disturbance and sensitivity to endotoxin in patients with advanced cancer: relationship to lymphocyte reactivity, tumour necrosis factor (TNF) production and survival. Clin Exp Immunol 1996; 105: 529-36.
20. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988; 2: 72-4.
21. Butcher E.C. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-6.
22. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
23. Sugahara S, Ichida T, Yamagiwa S et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 2002; 24: 346-54.
24. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams D.H. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174: 1055-62.
25. Tang TJ, Kwekkeboom J, Laman JD et al. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003; 10: 159-67.
26. Sprengers D, van der Molen RG, Kusters JG et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans J Hepatol 2006; 45: 182-9.